Skip to main content
Clinical Trials/CTRI/2022/07/043789
CTRI/2022/07/043789
Completed
Phase 4

A post market clinical follow up prospective study to evaluate safety and performance of Eye Preparations (Hypromellose 0.3% w/v Sodium Hyaluronate 0.1% w/v Eye Drops).

STERICON PHARMA PRIVATE LIMITED0 sites54 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: H28- Cataract in diseases classified elsewhere
Sponsor
STERICON PHARMA PRIVATE LIMITED
Enrollment
54
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Pms

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subjects who experience dryness, Itchiness, discomfort of eyes due to the continuous use of computer/TV/exposed pollution/dry environment
  • \-Subjects wearing contact lenses who experience dryness, Itchiness, discomfort of eyes due to the continuous use of computer/TV/exposed pollution/dry environment

Exclusion Criteria

  • \-Subjects who are not willing to participate in the study
  • \-Anyone with known allergic reaction to Hypromellose \+Sodium Hyaluronate eye drops
  • \-Subjects with existing eye infection
  • \-Subjects undergone recent (6 weeks) cataract surgery who are on other eye medication

Outcomes

Primary Outcomes

Not specified

Similar Trials